Drugs / POLB 001
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT05765955 Comparator | Jul → Dec 2022 | influenza | Poolbeg Pharma plc | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | POLB 001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05765955 ↗ |
| Action | Inhibit | “p38 MAPK Inhibitor” NCT05765955 ↗ |